TrialThe Lancet. Microbe2024

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.

Richard T Davey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.